



NYC Builds Bio+
IN COLLABORATION WITH
Genetic Engineering & Biotechnology News

#SHUTDOWNSTEM AND BLACK LIVES MATTER: A CALL FOR DIVERSITY IN SCIENCE, MEDICINE & ACADEMIA

EVENT SPONSOR



On June 10, 2020, thousands of researchers around the world paused their work to support the ongoing Black Lives Matter movement and efforts against racism in the scientific community and society at large. Responding to calls from organizations such as Strike For Black Lives, #ShutDownSTEM and #ShutDownAcademia, individuals in university laboratories, scientific societies, technical journals and many others engaged in a week of communication on Twitter, participated in local protests and studied the history of systemic racism in virtual education events, ceased to announce new submissions for publications, and marched on their scientific institutions.

These events were meant to call attention to the dramatic disparity in representation, retention and recruitment of black scientists and doctors in academia, where only 9% of STEM workers in the US are black compared to 69% who are white, according to the PEW Center. Black professors made up only about 2% of full-time professors in 2017. These efforts followed the publication of the First Annual Report on Measuring Diversity in the Biotech Industry by the Biotechnology Industry Organization in January 2020.

Join NYC Builds Bio+, NYC executives and investors from academia, pharma, biotech and venture capital to discuss this structural and continuing lack of diversity in the industry, as well as the road ahead towards change.

AGENDA

1:00 PM - 1:05 PM Welcome & Overview of the Meeting

Nancy J Kelley, President & CEO, Nancy J Kelley + Associates



Nancy J. Kelley, President and CEO of Nancy J Kelley & Associates, is a nationally recognized executive and lawyer who has driven key strategic initiatives in science and medicine for over twenty years. Nancy J Kelley + Associates (NJK+A) builds things that matter for science and medicine in order to solve some of the world's most intractable problems. Whether advancing translational genomic research that has the potential to cure human disease and improve quality of life or facilitating ways that we can feed, fuel and heal the world through technological innovation in biology, NJK+A is committed to delivering scientific and medical breakthroughs. www.nancyjkelly.com

Ms. Kelley was the Founding Executive Director of the New York Genome Center. From its establishment in 2010 by its 11 Institutional Founding Members, she led the Center from a start-up to a fully operational, world class genomics research center and provider of cutting edge sequencing and bioinformatics services, raising \$110 million to do so. Her prior leadership history includes work in scientific institutions, life science companies, and life science real estate development. She has overseen major development projects for clients such as the National Institutes of Health, Johns Hopkins University, the Massachusetts Institute of Technology and Boston University/ Boston Medical Center. She also led the site selection and build out for the 173,00 sq ft facility of the New York Genome Center.



Tim Sanders, Senior Investment Officer, Ventas

Tim Sanders has been employed at Ventas Inc. since 2015 as a Senior Investment Officer. Tim is responsible for originating life science real estate acquisitions in the eastern half of the United States and Canada. He also works on ground up development of office and lab space in conjunction with Ventas' development partner, Wexford Science and Technology. The projects are mixed use developments including office, hotel and residential. They are located on or adjacent to university campuses, including Brown, Washington University, Penn and University of Maryland. Tim is currently responsible for over 1M sf of development projects expected to deliver in 2020 and 2021. He has more than 15 years of seniors housing finance experience and has held various positions with GE Capital Healthcare Financial Services. Additionally, Tim started and led the senior housing group at Marathon Asset Management originating over \$1B in financings during his tenure. He was also the President of the bridge lending business at Capital Funding Group ("CFG"). His career also includes 15 years of commercial banking and corporate finance work, including stints with Crestar Bank (SunTrust) and the Pension Benefit Guaranty Corporation.

Mr. Sanders received his B.B.A. from Howard University and an M.B.A. from the University of Pittsburgh.

1:05 PM - 1:50 PM Panel Presentation

MODERATOR:



Anthony Johnson, President & CEO, Kodikaz, Founding Partner, Buffalo Biosciences

Anthony Johnson is an experienced executive with a strong track record of leadership across the healthcare sector. His experience has covered a multitude of areas inclusive of sales, marketing and strategy and business development. Having lived and worked in Europe, South America and the USA Mr. Johnson brings an international perspective and diversity of domestic and international experiences to his work.

Anthony is the former President/CEO of Empire Genomics, a pre-eminent oncology genomic molecular diagnostic company. As the founding CEO of Empire he led the business through multiple funding rounds, acquisitions, licensing in addition to staffing and setting business strategy. Under his guidance Empire was able to launch companion diagnostic assays, obtain CAP and CLIA certifications, CE marking and move 3 times to accommodate business growth. Anthony also founded Buffalo Biosciences, (BBS) a technology investment and management services firm. At BBS Anthony worked with clients including tech transfer offices, numerous startups in addition to State and Local Governments to guide them in their focus on healthcare endeavors. A major accomplishment that Anthony led on behalf of BBS was the firm's participation in the creation and launch of the New York Stem Genome Center. Prior to Buffalo Biosciences he led the stem cell and cell therapy division for IVGN corporation (Life Technologies). In this capacity he was responsible for sales, marketing and business development. In this role Mr. Johnson was responsible for IVGN's participation in the creation of the California Institute for Regenerative Medicine, a \$3 Billion dollar bond issuance to support stem cell research in the state.



Nancy J Kelley, President & CEO, Nancy J Kelley + Associates

FEATURED SPEAKERS:



Asha S. Collins, PhD, Head of US, Country Clinical Operations, Genentech and Aspen Institute Health Innovators Fellow

Dr. Asha S. Collins is the US country head for country clinical operations at Genentech, a member of the Roche Group. She is responsible for leading the team that executes in-sourced, late-stage, pivotal clinical trials across all US sites for Genentech and Roche. Previously, she led the US Clinical Trial Sourcing business at McKesson Corporation, one of North America's largest healthcare organizations. In this position, she successfully restructured the multi-hundred-million-dollar business that sources commercial products for research. Within the first year, she established a new organizational operating model, implemented a new technology platform, and standardized processes across a matrix organization that spans the US. Prior to McKesson, Asha was a management consultant focused on creating new operating models for leading biopharmaceutical companies.



Emmanuel F. Fombu, MD, MBA, Venture Partner, FundRx, VP Locust Walk Partners, Author: The Future of Healthcare, Prior Medical Director Novartis, Bayer, Johnson & Johnson

Emmanuel Fombu, MD, MBA, is a physician, speaker and healthcare executive turned Silicon Valley entrepreneur. As a medical futurist and 2017 winner of the prestigious New York City Health Business Leaders Boldest Digital Health Influencer Award, Dr. Fombu champions the potential for the internet of things, artificial intelligence and machine learning to revolutionize the healthcare industry.



Mark Hicks, Associate Scientist: Cell Biology, Lab Manager & HSE (Health, Safety, Environment) Representative, Loxo Oncology at Eli Lilly Corp

Mark Hicks II is an Associate Scientist in Cell Biology, Laboratory Manager, and Health, Safety & Environment (HSE) representative for Loxo Oncology at Eli Lilly and Company. In his role Mark coordinates laboratory operations, oversees and maintains health and safety regulations, and provides extensive scientific and technical expertise in a variety of molecular assays related to cancer biology and immunology. Prior to this, Mark was a Senior Research Associate & Lab Manager at Petra Pharma Corporation, a clinical-stage pharmaceutical company founded by Dr. Nathanael Gray (Harvard Medical School/Dana Farber Cancer Institute) and Dr. Lewis Cantley (Weill Cornell Medicine) that focused on the development of novel therapies which modulate phosphoinositide (PI) signaling pathways for the treatment of cancer.



Ann-Gel Palermo, DrPH, MPH, Associate Dean for Diversity & Inclusion, Chief Program Officer/Co-Founder, Diversity Innovation Hub, Icahn School of Medicine at Mount Sinai

Ann-Gel S. Palermo is the Chief Program Officer of the Office for Diversity and Inclusion (ODI) of the Mount Sinai Health System and the Associate Dean for Diversity and Inclusion in Biomedical Education at the Icahn School of Medicine at Mount Sinai. Dr. Palermo has developed a career portfolio that reflects the intersection among diversity affairs, medical education, and community-based public health practice and research. Dr. Palermo's work in diversity affairs at ISMMS aims to foster a holistic and equitable medical education training experience for students and faculty with a primary focus on individuals from disadvantaged and or underrepresented backgrounds in medicine and science. Some of Dr. Palermo's specific contributions to ISMMS' educational platform include developing and delivering curricula addressing racism and bias in clinical medicine, integration of social contemporary issues into graduate and medical education, advancing a holistic and equitable approach to student and curricular affairs practices and policies, and serving as the faculty advisor to 15 medical and graduate student-led organizations and initiatives focused on youth and community engagement as well as service and advocacy.



Tim Sanders, Senior Investment Officer, Ventas

1:50 PM - 2:00 PM Q&A with Audience

2:00 PM - 2:30 PM Networking Connect

FOUNDING MEMBERS



2020 CORPORATE MEMBERS



NYC BUILDS BIO+